Haibo Pharmaceutical

Haibo (Shanghai) Pharmaceutical Technology is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the discovery and development of novel small molecule therapeutics for cancer and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target complex biological mechanisms, with a particular emphasis on the ubiquitin-proteasome system and the MAPK signaling pathway. Its lead candidate, HB-001, is a selective inhibitor of USP7 currently in Phase 1 clinical trials for advanced solid tumors. Beyond its lead program, Haibo is advancing a robust pipeline of preclinical assets targeting HPK1, MCL-1, and SOS1. The company aims to deliver precision medicines that address significant unmet needs in oncology through innovative chemistry and rigorous translational research.